Statins may prevent depression, but do little to reduce depression when it is already present
STUDY: Debele GR et al, Journal of Affective Disorders 2026
STUDY TYPE: Cohort study designed to emulate a randomized trial
FUNDING: National Institutes of Health, Australian government grants, Monash University
Background
Statins lower cholesterol, and they also reduce inflammation and protect blood vessels, two pathways linked to late-life depression. Past studies disagree on whether they improve mood, and today’s paper is a large one that takes a long term view. That makes sense, as they probably do a better job at preventing these vascular risks than relieving them.
The Study
- 20,709 community-dwelling adults aged 70 and older from the ASPREE aspirin trial in Australia and the US.
- Two cohorts: 17,231 without depression at baseline (prevention) and 3,478 with depression (treatment). Statin users were compared with non-users.
- Median follow-up was 8.4 years, with yearly ratings on the Depression scale (CES-D-10).
Results
In people without depression, statin use was linked to a 20% lower risk of depressive symptoms (RR 0.80). The NNT was 42 at one year, 17 at five years, and 13 by study’s end (meaning you’d need to treat 13 people with a statin to prevent 1 depression).
The link was stronger in people with several medical conditions (relative risk, RR 0.77) or high genetic risk for depression (RR 0.73).
In people who already had depression, statins made no difference overall (RR 1.03). Those with high genetic risk improved slightly (RR 0.84).
Liver abnormalities (a risk with statins) were rare and equal in both groups (0.3%).
Limitations
Not randomized, so confounding is possible, and depression was measured by a screening scale rather than diagnosis. In people who started statins mid-study, the benefit shrank and lost statistical certainty (HR 0.87).
Practice Implications
- What’s good for the heart is good for the brain, especially in later life, and this study agrees.
- However, statins are linked to rare memory problems, liver disease, and — more commonly — muscle aches.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report
